Volume 156, Issue 6, Pages (May 2019)

Slides:



Advertisements
Similar presentations
Volume 148, Issue 7, Pages e6 (June 2015)
Advertisements

Gastrointestinal Stromal Tumors: Disease and Treatment Update
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 132, Issue 3, Pages (March 2007)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Volume 138, Issue 5, Pages e1 (May 2010)
Volume 144, Issue 5, Pages (May 2013)
Volume 151, Issue 2, Pages (August 2016)
Covering the Cover Gastroenterology
Covering the Cover Gastroenterology
Genetics and Genomics in the Practice of Medicine
Effectiveness of Hepatitis B Treatment in Clinical Practice
Volume 153, Issue 4, Pages (October 2017)
Is HCV Infection a Neurologic Disorder?
Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection  Tobias Boettler, Robert Thimme  Gastroenterology 
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 154, Issue 1, Pages e6 (January 2018)
Volume 137, Issue 5, Pages (November 2009)
Volume 132, Issue 2, Pages (February 2007)
Volume 134, Issue 5, Pages (May 2008)
Volume 145, Issue 1, Pages (July 2013)
Covering the Cover Gastroenterology
Volume 135, Issue 4, Pages (October 2008)
A Historical Perspective on Clinical Advances in Pancreatic Diseases
Volume 150, Issue 4, Pages (April 2016)
Volume 154, Issue 4, Pages (March 2018)
Volume 155, Issue 5, Pages e2 (November 2018)
Jean-Michel Pawlotsky  Gastroenterology 
Liver Sinusoidal Endothelial Cells: An Antiviral “Defendothelium”
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Navigating the Maze of Hepatitis B Treatments
Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill
Volume 145, Issue 1, Pages (July 2013)
Volume 142, Issue 6, Pages e3 (May 2012)
Covering the Cover Gastroenterology
Volume 142, Issue 6, Pages (May 2012)
Covering the Cover Gastroenterology
High Fever After Radiofrequency Ablation of Hepatocellular Carcinoma
Covering the Cover Gastroenterology
Volume 133, Issue 2, Pages (August 2007)
Interleukin-28b: A Key Piece of the Hepatitis C Virus Recovery Puzzle
Targeted Therapies for Hepatocellular Carcinoma
Ashwin N. Ananthakrishnan, David Lieberman  Gastroenterology 
Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis  Karin L. Andersson, Joshua A. Salomon,
Volume 148, Issue 3, Pages (March 2015)
Antoine Debourdeau, Anne Bozon, Romain Altwegg  Gastroenterology 
Jeremy P. Dwyer, Patrick Hosking, John Lubel  Gastroenterology 
Volume 149, Issue 6, Pages (November 2015)
Volume 150, Issue 7, Pages (June 2016)
Covering the Cover Gastroenterology
The Dawning of a New Editorial Board for Gastroenterology
Richard J. Saad, William D. Chey  Gastroenterology 
Volume 132, Issue 3, Pages (March 2007)
Richard Blumberg, Judy Cho, James Lewis, Gary Wu  Gastroenterology 
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Long Noncoding RNAs and Hepatocellular Carcinoma
Liver Transplantation for Hepatocellular Carcinoma
Volume 156, Issue 3, Pages (February 2019)
Volume 155, Issue 6, Pages (December 2018)
Volume 139, Issue 6, Pages e1 (December 2010)
Volume 135, Issue 6, Pages (December 2008)
Reply Gastroenterology
End-Stage Liver Disease in 2008: Finally a Glass Half Full
Josep M. Llovet, Robert Montal, Augusto Villanueva 
Covering the Cover Gastroenterology
Volume 151, Issue 2, Pages (August 2016)
Controversies in Liver Transplantation for Hepatitis C
Volume 156, Issue 4, Pages (March 2019)
Volume 141, Issue 1, Pages (July 2011)
Volume 146, Issue 4, Pages (April 2014)
Presentation transcript:

Volume 156, Issue 6, Pages 1731-1741 (May 2019) Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma  Michael Teufel, Henrik Seidel, Karl Köchert, Gerold Meinhardt, Richard S. Finn, Josep M. Llovet, Jordi Bruix  Gastroenterology  Volume 156, Issue 6, Pages 1731-1741 (May 2019) DOI: 10.1053/j.gastro.2019.01.261 Copyright © 2019 AGA Institute Terms and Conditions

Figure 1 RESORCE patient subgroups for biomarker analyses. Gastroenterology 2019 156, 1731-1741DOI: (10.1053/j.gastro.2019.01.261) Copyright © 2019 AGA Institute Terms and Conditions

Figure 2 Hierarchical clustering of baseline gene expression data for (A) all 46 samples (32 regorafenib, 14 placebo) and (B) 32 samples from regorafenib-treated patients. DC, dendritic cell; HBV, hepatitis B virus; HCV, hepatitis C virus; N, no; NK, natural killer; Th1, type 1 T helper cell; Treg, regulatory T cell; Y, yes. Gastroenterology 2019 156, 1731-1741DOI: (10.1053/j.gastro.2019.01.261) Copyright © 2019 AGA Institute Terms and Conditions

Figure 3 Protein dichotomized subgroup analysis for OS regorafenib treatment benefit. Error bars denote 95% CIs of the treatment HR. Note, the HR reference level line was set to 1. HR <1 indicates regorafenib treatment benefit. Dichotomized protein expression was categorized into high (>median) vs low (≤median). Cox models were adjusted for Eastern Cooperative Oncology Group performance status, AFP level, macrovascular invasion presence, geographical region, and extrahepatic disease presence. Gastroenterology 2019 156, 1731-1741DOI: (10.1053/j.gastro.2019.01.261) Copyright © 2019 AGA Institute Terms and Conditions